Evidence map›Paper›PMID 35036987›Full record

ArticleJournal of mass spectrometry and advances in the clinical lab2022

Development of a high-throughput differential mobility separation-tandem mass spectrometry (DMS-MS/MS) method for clinical urine drug testing.

Shirin Hooshfar, Simone Tchu, Cassandra Yun, Kara L Lynch

Open access · goldAbstract read
PubMed Full text at PMC Publisher
In one paragraph

Article in Journal of mass spectrometry and advances in the clinical lab, 2022. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 5 papers.

0numbers the graph read from it
0cells of the map it votes in
5citing papers in PubMed
1.4field-weighted citation impact, top 21% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

5 citing papers in PubMed, 13 citations in OpenAlex.

  1. Article
  2. Article
  3. The Multifaceted Impact of Bioactive Lipids on Gut Health and Disease.International journal of molecular sciences · 2024
    Review
  4. Improving LC-MS/MS measurements of steroids with differential mobility spectrometry.Journal of mass spectrometry and advances in the clinical lab · 2023
    Article
  5. Advances in MS instrumentation: The present and future of the clinical lab.Journal of mass spectrometry and advances in the clinical lab · 2022
    Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

4 authors at 1 institution in 1 country.

Shirin HooshfarDepartment of Laboratory Medicine, University of California San Francisco, San Francisco, CA, United States.
Simone TchuDepartment of Laboratory Medicine, University of California San Francisco, San Francisco, CA, United States.
Cassandra YunDepartment of Laboratory Medicine, University of California San Francisco, San Francisco, CA, United States.
Kara L LynchDepartment of Laboratory Medicine, University of California San Francisco, San Francisco, CA, United States.
University of California, San Francisco · US

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

introductionDifferential mobility separation (DMS) is an analytical technique used for rapid separation of ions and isomers based on gas phase mobility prior to entering a mass spectrometer for analysis. The entire DMS process is accomplished in fewer than 20 ms and can be used as a rapid alternative to chromatographic separation.

objectiveThe primary objective was to evaluate the utility of DMS-tandem mass spectrometry (DMS-MS/MS) as a replacement for immunoassay-based clinical toxicology testing.

methodsA sensitive DMS-MS/MS method was developed and validated for simultaneous identification of 33 drugs and metabolites in human urine samples. After DMS optimization, the method was validated and used to screen 56 clinical urine samples. These results were compared to results obtained by immunoassay.

resultsThe DMS-MS/MS method achieved limits of detection ranging from 5 to 100 ng/mL. Moreover, the total analysis time was 2 min per sample. For the method performance evaluation, DMS-MS/MS results were compared with previously obtained urine toxicology immunoassay results. DMS-MS/MS showed higher sensitivity and identified 20% more drugs in urine, which were confirmed by LC-MS/MS.

conclusionThe DMS-MS/MS as applied in our lab demonstrated the capability for rapid drug screening and provided better analytical performance than immunoassay.

Indexed as

6-MAM, 6-MonoacetylmorphineAMPH, amphetamines/ecstasyBENZ, benzodiazepinesBUPR, buprenorphineCE, Collision energyCOV, compensation voltageCXP, collision cell exit potentialDAPPI, atmospheric pressure photo ionizationDART, direct analysis in real timeDC, direct currentDESI, desorption electrospray ionizationDifferential mobility separationDMO, DMS offseDMS, differential mobility separationDP, declustering potentialDR, DMS resolution enhancementDrugs of abuseDT, DMS cell temperatureEDDP, 2-ethylidene1,5-dimethyl-3,3-diphenylpyrrolidineEP, entrance potentialFAIMS, field asymmetric waveform ion mobility spectrometryFSI, fiber spray ionizationGC-MS or LC-MS, gas chromatography- or liquid chromatography-mass spectrometryGS1, ion source gas 1GS2, ion source gas 2IMS, ion mobility spectrometry, IS, internal standards, LOD, limit of detection, MD, modifier, MDC, modifier composition, ME, matrix effectsMass spectrometryMRM, multiple reaction monitoringMS/MS, tandem mass spectrometryOPI, opiatesOXY, oxycodone/oxmorphoneQCs, quality controlsSRM, selected reaction monitoringSV, separation voltageUrine drug screeningWT-ESI, wooden-tip electrospray ionization

Identifiers

PMID35036987
PMCPMC8753179
OpenAlexW4206783891

What OpenQuestion holds

Textmetadata
LicenceCC BY-NC-ND
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.